On July 3, 2024, San Ye Cao Biotechnology Co., Ltd. ("San Ye Cao Biotechnology-B") submitted its latest monthly report on securities changes to Hong Kong Exchanges and Clearing Limited, reporting on the shareholding changes as of June 30, 2024. The report shows that the company's statutory/registered share capital remains unchanged, totaling USD 200,000 with a par value of USD 0.0001 per share, and a total number of issued shares of 2,000,000,000. In terms of issued shares, the company only increased its ordinary shares by 1,500 in June, bringing the total number of issued shares at the end of the month to 1,297,048,929. In addition, there have been changes in both the pre-ipo share option plan and the post-ipo share option plan in the company...Show More

On July 3, 2024, San Ye Cao Biotechnology Co., Ltd. ("San Ye Cao Biotechnology-B") submitted its latest monthly report on securities changes to Hong Kong Exchanges and Clearing Limited, reporting on the shareholding changes as of June 30, 2024. The report shows that the company's statutory/registered share capital remains unchanged, totaling USD 200,000 with a par value of USD 0.0001 per share, and a total number of issued shares of 2,000,000,000. In terms of issued shares, the company only increased its ordinary shares by 1,500 in June, bringing the total number of issued shares at the end of the month to 1,297,048,929. In addition, there have been changes in both the pre-ipo share option plan and the post-ipo share option plan in the company's share option plan, with the latter decreasing by 2,523,213 shares due to the options expiring. The company confirms that all sales or transfers of securities issued or in stock have been formally authorized and approved by the board of directors and comply with all applicable listing rules, laws, and other regulatory requirements.